Prenetics Global Business Summary

Prenetics Global Ltd (PRE) is a pure-play consumer health and longevity company that generates revenue primarily through high-margin direct-to-consumer (D2C) transactions and recurring subscriptions. Following a comprehensive 2025-2026 strategic pivot, the company divested its clinical and B2B assets—including ACT Genomics, Europa Sports Partners, and its minority stake in the Insighta cancer-detection venture—to focus exclusively on its flagship premium nutrition brand, IM8, and its consumer genomics arm, CircleDNA. The business model centers on the IM8 "Daily Ultimate Essentials" ecosystem, which is projected to reach $180 million to $200 million in revenue for FY2026 with a target gross margin of 60%. In the competitive landscape, Prenetics competes with premium supplement and longevity firms such as AG1 (Athletic Greens) and Thorne HealthTech, as well as consumer genomics peers like 23andMe. The company distinguishes itself through a science-backed, celebrity-endorsed "all-in-one" health optimization platform and a robust balance sheet featuring $171.1 million in liquidity and zero debt as of February 2026. The company is led by Co-founder and CEO Danny Yeung, a serial entrepreneur and former CEO of Groupon Hong Kong, alongside Co-founder and Chief Scientific Officer Dr. Lawrence Tzang, a specialist in molecular diagnostics. The leadership team includes Chief Financial Officer Stephen Lo, Chief Consumer Officer Joel Neoh (founder of Fave), and David Vanderveen, President of Americas, who previously scaled Amway’s XS Energy brand to $400 million in annual sales. Prenetics’ strategic direction is heavily influenced by its co-founding partner, David Beckham, and a board of directors that includes longevity expert Dr. Darshan Shah (appointed February 2026) and Ben Cheng of C Capital. Notable institutional backing includes the Alibaba Hong Kong Entrepreneurs Fund, Prudential, and Adrian Cheng, while the recent $70 million divestiture of Insighta to Tencent underscores the company's ability to monetize non-core R&D assets to fund its global consumer expansion.